Neuraceq® Scan

Neuraceq® Scan
dot dot dot

dot

Neuraceq® delivers sensitive and reliable detection of β-amyloid neuritic plaques

Neuraceq® is an accurate diagnostic tool to aid in the evaluation of cognitive decline.1 Neuraceq® reveals β-amyloid neuritic plaques in different brain regions, thereby allowing an estimate of plaque density by degree of uptake.1

Negative Neuraceq Scan

Negative Scans

Top row images are negative scans, corresponding to lower tracer uptake in gray matter than white matter, and reduced likelihood that cognitive decline is a result of AD

Positive Neuraceq Scan

Visual assessment is based on the systematic comparison of tracer uptake in gray and white matter, focusing on specific cortical regions, as seen in greyscale images.

1Neuraceq® (florbetaben F18 injection) prescribing information. Life Molecular Imaging; June 2025. Fareham, UK.

Positive Scans

Images show positive scans with equal or higher tracer uptake in gray matter than white matter and moderate to frequent β-amyloid neuritic plaques

dot

Neuraceq® scan reports can help facilitate dialogue between physicians, patients, and caregivers

While the actual diagnosis is made by reading the black and white scans, useful reports provided to you by your patient’s imaging specialist include an accompanying written assessment.

dot

The Neuraceq® scan is convenient for patients

Neuraceq® provides a wide, stable scan window of 45-130 minutes, and a 15-20 minute scan time, making the process quick and convenient for your patients. A Neuraceq® PET scan involves an injection into a vein in the arm and a short scan.

Injection

Neuraceq® injection

Wait time

Wait 45+ minutes

PET scan

PET Scan

Scan complete

Scan completed

 
 

Frequently Asked Questions about Neuraceq®

Neuraceq® was FDA approved in March 2014 and is available in many imaging centers across the US.

Contact Your Rep for specific details on Neuraceq® availability in your area.

Neuraceq® can give you important information in cases where Alzheimer’s disease is suspected. If the scan is positive, it means that beta amyloid plaques are present in the brain. If the scan is negative, it means that beta amyloid plaques are not present, and another diagnosis can be considered. View the USPI for more information.

Early detection and intervention can benefit patients. Having a diagnosis gives patients the opportunity to plan ahead. Pharmacological and non-pharmacological interventions can begin sooner. Knowing a diagnosis gives patients the opportunity to receive treatment with FDA-approved amyloid-targeting therapies.

Our patient and caregiver information can be viewed on our patient and caregiver page. To request digital or printed materials, simply use the map to find your Neuraceq® representative and reach out directly.

Contact Us for more information.

FIND OUT ABOUT REIMBURSEMENT

Neuraceq® - Product Indications And Use

PRODUCT INDICATIONS AND USE: NEURACEQ is a radioactive diagnostic drug indicated for positron emission tomography (PET) of the brain to estimate amyloid beta neuritic plaque density in adults with cognitive impairment for:  Evaluation of Alzheimer’s disease (AD) and other causes of cognitive decline, and selection of patients who are indicated for amyloid beta-directed therapy as described in the prescribing information of the therapeutic products.

 

NEURACEQ IMPORTANT SAFETY INFORMATION:

 

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

  • Risk for Image Misinterpretation and other Errors
    NEURACEQ Risk of Image Misinterpretation and Other Errors: Image interpretation errors have been observed. [see Section 5.1 of the full prescribing information]
  • Radiation Risk
    NEURACEQ, similar to other radiopharmaceuticals, contributes to a patient's overall long-term cumulative radiation exposure. Long-term cumulative radiation exposure is associated with an increased risk of cancer. Ensure safe handling to protect patients and health care workers from unintentional radiation exposure [see Dosage and Administration in the full prescribing information].

ADVERSE REACTIONS:

  • The most commonly reported adverse reactions in clinical trials were injection site pain (3.4%), injection/application site erythema (1.7%), and injection site irritation (1.1%).

USE IN SPECIFIC POPULATIONS:

  • Pregnancy : All radiopharmaceuticals, including NEURACEQ, have a potential to cause fetal harm depending on the stage of fetal development and the magnitude of the radiopharmaceutical dose. If considering NEURACEQ administration to a pregnant woman, inform the patient about the potential for adverse pregnancy outcomes based on the radiation dose from the drug and the gestational timing of exposure.
  • Lactation : Temporarily discontinue breastfeeding. A lactating woman should pump and discard breast milk for 24 hours after NEURACEQ administration.
  • Pediatric Use:  The safety and effectiveness of NEURACEQ have not been established in pediatric patients.
  • Geriatric Use: No overall differences in safety or effectiveness were observed between subjects 65 years of age and older and younger adult subjects.

OVERDOSAGE:
 In the event of administration of a radiation overdose with NEURACEQ, the absorbed organ dose to the patient should be reduced by increasing elimination of the radionuclide from the body by inducing frequent micturition. Prior to NEURACEQ administration, please read the full Prescribing Information for additional Important Safety Information.

SUSPECTED ADVERSE REACTIONS: please report to: https://www.fda.gov/safety/medwatch-fda-safety-information-and-adverse-event-reporting-program

X